価格表

在庫・価格 : 2024年06月19日 13時42分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-Fanconi anemia D2, Rabbit-Poly, Sample Size
データシート※最新のデータシートでない場合があります
NB100-182SS NOVノバス バイオロジカルス
Novus biologicals, LLC
0.025 ml ¥60,000
(未発注)
追加

在庫・価格 : 2024年06月19日 13時42分 現在

Anti-Fanconi anemia D2, Rabbit-Poly, Sample Size

  • 商品コード:NB100-182SS
  • メーカー:NOV
  • 包装:0.025ml
  • 価格: ¥60,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Brem R et al. UVA photoactivation of DNA containing halogenated thiopyrimidines induces cytotoxic DNA lesions. J. Photochem. Photobiol. B, Biol. 2015 Apr;145:1-10
Brem R et al
2015/01/01
Species: Human, Applications: WB PubMed
2 Chlon TM et al. High-risk human papillomavirus E6 protein promotes reprogramming of Fanconi anemia patient cells through repression of p53 but does not allow for sustained growth of induced pluripotent stem cells. J. Virol. 2014 Oct;88(19):11315-26
Chlon TM et al
2014/01/01
Species: Human, Applications: WB PubMed
3 Stoepker C et al. DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity. DNA Repair (Amst.) 2015 Feb;26:54-64
Stoepker C et al
2015/01/01
Species: Human, Applications: ICC/IF PubMed
4 Panneerselvam J et al. Basal level of FANCD2 monoubiquitination is required for the maintenance of a sufficient number of licensed-replication origins to fire at a normal rate. Oncotarget 2014 Mar;5(5):1326-37
Panneerselvam J et al
2014/01/01
Species: Human, Applications: WB PubMed
5 Bursomanno S et al. Proteome-wide analysis of SUMO2 targets in response to pathological DNA replication stress in human cells. DNA Repair (Amst.) 2015 Jan;25:84-96
Bursomanno S et al
2015/01/01
Species: Human, Applications: WB PubMed
6 Duan W et al. Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer. Front Oncol 2014;4:368
Duan W et al
2014/01/01
Species: Human, Applications: WB, IHC-P PubMed
7 Tremblay S et al. Young patients with oral squamous cell carcinoma: study of the involvement of GSTP1 and deregulation of the Fanconi anemia genes. Arch. Otolaryngol. Head Neck Surg. 2006 Sep;132(9):958-66
Tremblay S et al
2006/01/01
Species: Human, Applications: IHC-P PubMed
8 An JY et al. UBR2 of the N-end rule pathway is required for chromosome stability via histone ubiquitylation in spermatocytes and somatic cells. PLoS ONE 2012;7(5):e37414
An JY et al
2012/01/01
Species: Mouse, Applications: ICC/IF PubMed
9 Duan W et al. Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. Transl Res 2012 Oct;
Duan W et al
2012/01/01
Species: Human, Applications: ICC/IF, IHC PubMed
10 Howlett NG et al. Functional interaction between the Fanconi Anemia D2 protein and proliferating cell nuclear antigen (PCNA) via a conserved putative PCNA interaction motif. J. Biol. Chem. 2009 Oct;284(42):28935-42
Howlett NG et al
2009/01/01
Species: Human, Applications: WB PubMed
11 Ceccaldi R et al. Bone marrow failure in fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell 2012 Jul;11(1):36-49
Ceccaldi R et al
2012/01/01
Species: Human, Applications: WB, ICC/IF PubMed
12 Leung JW et al. Fanconi anemia (FA) binding protein FAAP20 stabilizes FA complementation group A (FANCA) and participates in interstrand cross-link repair. Proc. Natl. Acad. Sci. U.S.A. 2012 Mar;109(12):4491-6
Leung JW et al
2012/01/01
Species: Human, Applications: WB, ICC/IF PubMed
13 Mukhopadhyay SS et al. Defective mitochondrial peroxiredoxin-3 results in sensitivity to oxidative stress in Fanconi anemia. J. Cell Biol. 2006 Oct;175(2):225-35
Mukhopadhyay SS et al
2006/01/01
Species: Human, Applications: WB PubMed
14 Rothfuss A et al. Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the Fanconi anemia/BRCA pathway. Mol. Cell. Biol. 2004 Jan;24(1):123-34
Rothfuss A et al
2004/01/01
Species: Human, Applications: WB, ICC/IF PubMed
15 Aarts M et al. Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways. Mol. Cancer Ther. 2015 Apr;14(4):865-76
Aarts M et al
2015/01/01
Species: Human, Applications: WB PubMed
16 Digweed M et al. Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia. Carcinogenesis 2002 Jul;23(7):1121-6
Digweed M et al
2002/01/01
Applications: PubMed
17 Sridharan D et al. Nonerythroid alphaII spectrin is required for recruitment of FANCA and XPF to nuclear foci induced by DNA interstrand cross-links. J. Cell. Sci. 2003 Mar;116(Pt 5):823-35
Sridharan D et al
2003/01/01
Species: Human, Applications: WB, ICC/IF, IP PubMed
18 Yüce Ö et al. Senataxin, defective in the neurodegenerative disorder ataxia with oculomotor apraxia 2, lies at the interface of transcription and the DNA damage response. Mol. Cell. Biol. 2013 Jan;33(2):406-17
Yüce Ö et al
2013/01/01
Species: Human, Applications: ICC/IF PubMed
19 Colnaghi L et al. Patient-derived C-terminal mutation of FANCI causes protein mislocalization and reveals putative EDGE motif function in DNA repair. Blood 2011 Feb;117(7):2247-56
Colnaghi L et al
2011/01/01
Species: Human, Applications: ICC/IF PubMed
20 Ceccaldi R et al. Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients. J. Clin. Invest. 2011 Jan;121(1):184-94
Ceccaldi R et al
2011/01/01
Species: Human, Applications: WB PubMed
21 Wright JW et al. Ovarian surface epitheliectomy in the non-human primate: continued cyclic ovarian function and limited epithelial replacement. Hum. Reprod. 2011 Jun;26(6):1422-30
Wright JW et al
2011/01/01
Species: Primate, Applications: IHC-P PubMed
22 Hovest MG et al. Differential roles for Chk1 and FANCD2 in ATR-mediated signalling for psoralen photoactivation-induced senescence. Exp. Dermatol. 2011 Nov;20(11):883-9
Hovest MG et al
2011/01/01
Species: Human, Applications: WB, ICC/IF PubMed
23 Pf辰ffle HN et al. EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. Cancer Res. 2013 Oct;73(20):6254-63
Pf辰ffle HN et al
2013/01/01
Species: Human, Applications: ICC/IF PubMed
24 Mason JM et al. The SNM1B/APOLLO DNA nuclease functions in resolution of replication stress and maintenance of common fragile site stability. Hum. Mol. Genet. 2013 Jul;
Mason JM et al
2013/01/01
Species: Human, Applications: WB, ICC/IF PubMed
25 Ogi T et al. Identification of the first ATRIP-deficient patient and novel mutations in ATR define a clinical spectrum for ATR-ATRIP Seckel Syndrome. PLoS Genet. 2012;8(11):e1002945
Ogi T et al
2012/01/01
Species: Human, Applications: WB PubMed
26 Dunn J et al. Activation of the Fanconi anemia/BRCA pathway and recombination repair in the cellular response to solar ultraviolet light. Cancer Res. 2006 Dec;66(23):11140-7
Dunn J et al
2006/01/01
Applications: PubMed
27 McMahon LW et al. Human alpha spectrin II and the FANCA, FANCC, and FANCG proteins bind to DNA containing psoralen interstrand cross-links. Biochemistry 2001 Jun;40(24):7025-34
McMahon LW et al
2001/01/01
Species: Human, Applications: WB, IP PubMed
28 Bilardi RA et al. Processing of anthracycline-DNA adducts via DNA replication and interstrand crosslink repair pathways. Biochem. Pharmacol. 2012 May;83(9):1241-50
Bilardi RA et al
2012/01/01
Species: Mouse, Applications: ICC/IF PubMed
29 Jacquemont C et al. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Mol. Cancer 2012;11:26
Jacquemont C et al
2012/01/01
Species: Human, Applications: ICC/IF, WB PubMed
30 Yang Y et al. Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9. Blood 2001 Dec;98(12):3435-40
Yang Y et al
2001/01/01
Species: Mouse, Applications: WB PubMed
31 Stoepker C et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat. Genet. 2011 Feb;43(2):138-41
Stoepker C et al
2011/01/01
Species: Human, Applications: ICC/IF PubMed
32 Jun DW et al. Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agents. PLoS ONE 2013;8(10):e75905
Jun DW et al
2013/01/01
Species: Human, Applications: WB PubMed
33 Tomida J et al. A novel interplay between the Fanconi anemia core complex and ATR-ATRIP kinase during DNA cross-link repair. Nucleic Acids Res. 2013 May;
Tomida J et al
2013/01/01
Species: Human, Applications: WB PubMed
34 Boisvert RA et al. Coordinate nuclear targeting of the FANCD2 and FANCI proteins via a FANCD2 nuclear localization signal. PLoS ONE 2013;8(11):e81387
Boisvert RA et al
2013/01/01
Species: Human, Applications: WB, ICC/IF PubMed
35 Huard CC et al. The Fanconi anemia pathway has a dual function in Dickkopf-1 transcriptional repression. Proc. Natl. Acad. Sci. U.S.A. 2014 Feb;111(6):2152-7
Huard CC et al
2014/01/01
Species: Human, Applications: WB PubMed
36 Bhat A et al. Rev3, the catalytic subunit of Polζ, is required for maintaining fragile site stability in human cells. Nucleic Acids Res. 2013 Feb;41(4):2328-39
Bhat A et al
2013/01/01
Species: Human, Applications: ICC/IF PubMed
37 Kavanaugh GM et al. The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res. 2011 Sep;39(17):7465-76
Kavanaugh GM et al
2011/01/01
Species: Human, Applications: ICC/IF PubMed
38 Zhang P et al. Non-erythroid alpha spectrin prevents telomere dysfunction after DNA interstrand cross-link damage. Nucleic Acids Res. 2013 May;41(10):5321-40
Zhang P et al
2013/01/01
Species: Human, Applications: ICC/IF PubMed
39 Jones MJ et al. Dysregulation of DNA polymerase κ recruitment to replication forks results in genomic instability. EMBO J. 2012 Feb;31(4):908-18
Jones MJ et al
2012/01/01
Species: Human, Applications: ICC/IF PubMed
40 Bekker-Jensen S et al. Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J. Cell Biol. 2006 Apr;173(2):195-206
Bekker-Jensen S et al
2006/01/01
Species: Human, Applications: ICC/IF PubMed
41 Rego MA et al. Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor. Oncogene 2012 Jan;31(3):366-75
Rego MA et al
2012/01/01
Species: Human, Applications: WB, ICC/IF PubMed
42 Jacquemont C et al. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res. 2007 Aug;67(15):7395-405
Jacquemont C et al
2007/01/01
Species: Human, Applications: ICC/IF PubMed
43 Panneerselvam J et al. FAVL impairment of the Fanconi anemia pathway promotes the development of human bladder cancer. Cell Cycle 2012 Aug;11(15):2947-55
Panneerselvam J et al
2012/01/01
Species: Human, Applications: WB, ICC/IF PubMed
44 Lyakhovich A et al. Constitutive activation of caspase-3 and Poly ADP ribose polymerase cleavage in fanconi anemia cells. Mol. Cancer Res. 2010 Jan;8(1):46-56
Lyakhovich A et al
2010/01/01
Species: Human, Applications: WB PubMed
45 Wang Y et al. Structure analysis of FAAP24 reveals single-stranded DNA-binding activity and domain functions in DNA damage response. Cell Res. 2013 Oct;23(10):1215-28
Wang Y et al
2013/01/01
Species: Human, Applications: WB PubMed
46 Gravells P et al. Reduced FANCD2 influences spontaneous SCE and RAD51 foci formation in uveal melanoma and Fanconi anaemia. Oncogene 2013 Jan;
Gravells P et al
2013/01/01
Species: Human, Applications: WB PubMed
47 Baldeyron C et al. HP1alpha recruitment to DNA damage by p150CAF-1 promotes homologous recombination repair. J. Cell Biol. 2011 Apr;193(1):81-95
Baldeyron C et al
2011/01/01
Species: Human, Mouse, Applications: WB, ICC/IF PubMed
48 Stiff T et al. Nbs1 is required for ATR-dependent phosphorylation events. EMBO J. 2005 Jan;24(1):199-208
Stiff T et al
2005/01/01
Species: Human, Applications: ICC/IF PubMed
49 Wang Y et al. MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res. 2012 Aug;72(16):4037-46
Wang Y et al
2012/01/01
Species: Human, Applications: ICC/IF PubMed
50 Bhagwat N et al. XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair. Mol. Cell. Biol. 2009 Dec;29(24):6427-37
Bhagwat N et al
2009/01/01
Species: Human, Applications: WB, ICC/IF PubMed
51 Mason JM et al. Snm1B/Apollo functions in the Fanconi anemia pathway in response to DNA interstrand crosslinks. Hum. Mol. Genet. 2011 Jul;20(13):2549-59
Mason JM et al
2011/01/01
Species: Human, Applications: WB, ICC/IF PubMed
52 Oda T et al. Hsp90 regulates the Fanconi anemia DNA damage response pathway. Blood 2007 Jun;109(11):5016-26
Oda T et al
2007/01/01
Species: Human, Applications: WB PubMed
53 Taniguchi T et al. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 2002 Oct;100(7):2414-20
Taniguchi T et al
2002/01/01
Species: Human, Applications: WB, ICC/IF PubMed
54 Wang Y et al. FANCM and FAAP24 Maintain Genome Stability via Cooperative as Well as Unique Functions. Mol. Cell 2013 Mar;49(5):997-1009
Wang Y et al
2013/01/01
Species: Human, Applications: WB, ICC/IF PubMed
55 Taniguchi T et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 2003 May;9(5):568-74
Taniguchi T et al
2003/01/01
Species: Human, Applications: WB, IP, ICC/IF PubMed
56 Brem R et al. Efficient DNA interstrand crosslinking by 6-thioguanine and UVA radiation. DNA Repair (Amst.) 2011 Aug;10(8):869-76
Brem R et al
2011/01/01
Species: Human, Applications: WB PubMed
57 Coulthard R et al. Architecture and DNA recognition elements of the Fanconi anemia FANCM-FAAP24 complex. Structure 2013 Sep;21(9):1648-58
Coulthard R et al
2013/01/01
Species: Human, Applications: WB PubMed
58 Figueiredo N et al. Anthracyclines induce DNA damage response-mediated protection against severe sepsis. Immunity 2013 Nov;39(5):874-84
Figueiredo N et al
2013/01/01
Species: Human, Applications: WB PubMed
59 Donahue SL et al. A Rad50-dependent pathway of DNA repair is deficient in Fanconi anemia fibroblasts. Nucleic Acids Res. 2004;32(10):3248-57
Donahue SL et al
2004/01/01
Species: Human PubMed
60 Rego MA et al. Regulation of the Fanconi anemia pathway by a CUE ubiquitin-binding domain in the FANCD2 protein. Blood 2012 Sep;120(10):2109-17
Rego MA et al
2012/01/01
PubMed
61 Duquette ML et al. CtIP is required to initiate replication-dependent interstrand crosslink repair. PLoS Genet. 2012;8(11):e1003050
Duquette ML et al
2012/01/01
Species: Human, Applications: ICC/IF PubMed
62 Lensch MW et al. Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia. Blood 2003 Jul;102(1):7-16
Lensch MW et al
2003/01/01
Species: Human, Applications: WB PubMed
63 Garcia-Higuera I et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 2001 Feb;7(2):249-62
Garcia-Higuera I et al
2001/01/01
Species: Human, Applications: WB, ICC/IF PubMed
64 . ;

Species: Human, Applications: WB PubMed
65 Tremblay CS et al. HES1 is a novel interactor of the Fanconi anemia core complex. Blood 2008 Sep;112(5):2062-70
Tremblay CS et al
2008/01/01
Species: Human, Applications: WB, ICC/IF PubMed
66 Fu D et al. Recruitment of DNA polymerase eta by FANCD2 in the early response to DNA damage. Cell Cycle 2013 Mar;12(5):803-9
Fu D et al
2013/01/01
Species: Human, Applications: WB PubMed
67 Kolas NK et al. Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science 2007 Dec;318(5856):1637-40
Kolas NK et al
2007/01/01
PubMed
68 Jacome A et al. Lac operator repeats generate a traceable fragile site in mammalian cells. EMBO Rep. 2011 Oct;12(10):1032-8
Jacome A et al
2011/01/01
Species: Mouse, Applications: ICC/IF PubMed
69 Hoskins EE et al. The fanconi anemia pathway limits human papillomavirus replication. J. Virol. 2012 Aug;86(15):8131-8
Hoskins EE et al
2012/01/01
Species: Human, Applications: WB PubMed
70 Kim Y et al. Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4. Blood 2012 Oct;
Kim Y et al
2012/01/01
PubMed
71 Ying S et al. MUS81 promotes common fragile site expression. Nat. Cell Biol. 2013 Aug;15(8):1001-7
Ying S et al
2013/01/01
Species: Human, Applications: ICC/IF PubMed
72 Kim Y et al. Mutations of the SLX4 gene in Fanconi anemia. Nat. Genet. 2011 Feb;43(2):142-6
Kim Y et al
2011/01/01
Species: Human, Applications: WB PubMed
73 Olopade OI et al. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 2003 May;3(5):417-20
Olopade OI et al
2003/01/01
PubMed
  • No.: 1
  • 文献情報:
    Brem R et al. UVA photoactivation of DNA containing halogenated thiopyrimidines induces cytotoxic DNA lesions. J. Photochem. Photobiol. B, Biol. 2015 Apr;145:1-10
    Brem R et al
    2015/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Chlon TM et al. High-risk human papillomavirus E6 protein promotes reprogramming of Fanconi anemia patient cells through repression of p53 but does not allow for sustained growth of induced pluripotent stem cells. J. Virol. 2014 Oct;88(19):11315-26
    Chlon TM et al
    2014/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Stoepker C et al. DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity. DNA Repair (Amst.) 2015 Feb;26:54-64
    Stoepker C et al
    2015/01/01
  • 備考:
    Species: Human, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Panneerselvam J et al. Basal level of FANCD2 monoubiquitination is required for the maintenance of a sufficient number of licensed-replication origins to fire at a normal rate. Oncotarget 2014 Mar;5(5):1326-37
    Panneerselvam J et al
    2014/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Bursomanno S et al. Proteome-wide analysis of SUMO2 targets in response to pathological DNA replication stress in human cells. DNA Repair (Amst.) 2015 Jan;25:84-96
    Bursomanno S et al
    2015/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Duan W et al. Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer. Front Oncol 2014;4:368
    Duan W et al
    2014/01/01
  • 備考:
    Species: Human, Applications: WB, IHC-P
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Tremblay S et al. Young patients with oral squamous cell carcinoma: study of the involvement of GSTP1 and deregulation of the Fanconi anemia genes. Arch. Otolaryngol. Head Neck Surg. 2006 Sep;132(9):958-66
    Tremblay S et al
    2006/01/01
  • 備考:
    Species: Human, Applications: IHC-P
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    An JY et al. UBR2 of the N-end rule pathway is required for chromosome stability via histone ubiquitylation in spermatocytes and somatic cells. PLoS ONE 2012;7(5):e37414
    An JY et al
    2012/01/01
  • 備考:
    Species: Mouse, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Duan W et al. Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. Transl Res 2012 Oct;
    Duan W et al
    2012/01/01
  • 備考:
    Species: Human, Applications: ICC/IF, IHC
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Howlett NG et al. Functional interaction between the Fanconi Anemia D2 protein and proliferating cell nuclear antigen (PCNA) via a conserved putative PCNA interaction motif. J. Biol. Chem. 2009 Oct;284(42):28935-42
    Howlett NG et al
    2009/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Ceccaldi R et al. Bone marrow failure in fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell 2012 Jul;11(1):36-49
    Ceccaldi R et al
    2012/01/01
  • 備考:
    Species: Human, Applications: WB, ICC/IF
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Leung JW et al. Fanconi anemia (FA) binding protein FAAP20 stabilizes FA complementation group A (FANCA) and participates in interstrand cross-link repair. Proc. Natl. Acad. Sci. U.S.A. 2012 Mar;109(12):4491-6
    Leung JW et al
    2012/01/01
  • 備考:
    Species: Human, Applications: WB, ICC/IF
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Mukhopadhyay SS et al. Defective mitochondrial peroxiredoxin-3 results in sensitivity to oxidative stress in Fanconi anemia. J. Cell Biol. 2006 Oct;175(2):225-35
    Mukhopadhyay SS et al
    2006/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Rothfuss A et al. Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the Fanconi anemia/BRCA pathway. Mol. Cell. Biol. 2004 Jan;24(1):123-34
    Rothfuss A et al
    2004/01/01
  • 備考:
    Species: Human, Applications: WB, ICC/IF
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Aarts M et al. Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways. Mol. Cancer Ther. 2015 Apr;14(4):865-76
    Aarts M et al
    2015/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Digweed M et al. Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia. Carcinogenesis 2002 Jul;23(7):1121-6
    Digweed M et al
    2002/01/01
  • 備考:
    Applications:
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    Sridharan D et al. Nonerythroid alphaII spectrin is required for recruitment of FANCA and XPF to nuclear foci induced by DNA interstrand cross-links. J. Cell. Sci. 2003 Mar;116(Pt 5):823-35
    Sridharan D et al
    2003/01/01
  • 備考:
    Species: Human, Applications: WB, ICC/IF, IP
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Yüce Ö et al. Senataxin, defective in the neurodegenerative disorder ataxia with oculomotor apraxia 2, lies at the interface of transcription and the DNA damage response. Mol. Cell. Biol. 2013 Jan;33(2):406-17
    Yüce Ö et al
    2013/01/01
  • 備考:
    Species: Human, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 19
  • 文献情報:
    Colnaghi L et al. Patient-derived C-terminal mutation of FANCI causes protein mislocalization and reveals putative EDGE motif function in DNA repair. Blood 2011 Feb;117(7):2247-56
    Colnaghi L et al
    2011/01/01
  • 備考:
    Species: Human, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 20
  • 文献情報:
    Ceccaldi R et al. Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients. J. Clin. Invest. 2011 Jan;121(1):184-94
    Ceccaldi R et al
    2011/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 21
  • 文献情報:
    Wright JW et al. Ovarian surface epitheliectomy in the non-human primate: continued cyclic ovarian function and limited epithelial replacement. Hum. Reprod. 2011 Jun;26(6):1422-30
    Wright JW et al
    2011/01/01
  • 備考:
    Species: Primate, Applications: IHC-P
  • 参照:
    PubMed
  • No.: 22
  • 文献情報:
    Hovest MG et al. Differential roles for Chk1 and FANCD2 in ATR-mediated signalling for psoralen photoactivation-induced senescence. Exp. Dermatol. 2011 Nov;20(11):883-9
    Hovest MG et al
    2011/01/01
  • 備考:
    Species: Human, Applications: WB, ICC/IF
  • 参照:
    PubMed
  • No.: 23
  • 文献情報:
    Pf辰ffle HN et al. EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. Cancer Res. 2013 Oct;73(20):6254-63
    Pf辰ffle HN et al
    2013/01/01
  • 備考:
    Species: Human, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 24
  • 文献情報:
    Mason JM et al. The SNM1B/APOLLO DNA nuclease functions in resolution of replication stress and maintenance of common fragile site stability. Hum. Mol. Genet. 2013 Jul;
    Mason JM et al
    2013/01/01
  • 備考:
    Species: Human, Applications: WB, ICC/IF
  • 参照:
    PubMed
  • No.: 25
  • 文献情報:
    Ogi T et al. Identification of the first ATRIP-deficient patient and novel mutations in ATR define a clinical spectrum for ATR-ATRIP Seckel Syndrome. PLoS Genet. 2012;8(11):e1002945
    Ogi T et al
    2012/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 26
  • 文献情報:
    Dunn J et al. Activation of the Fanconi anemia/BRCA pathway and recombination repair in the cellular response to solar ultraviolet light. Cancer Res. 2006 Dec;66(23):11140-7
    Dunn J et al
    2006/01/01
  • 備考:
    Applications:
  • 参照:
    PubMed
  • No.: 27
  • 文献情報:
    McMahon LW et al. Human alpha spectrin II and the FANCA, FANCC, and FANCG proteins bind to DNA containing psoralen interstrand cross-links. Biochemistry 2001 Jun;40(24):7025-34
    McMahon LW et al
    2001/01/01
  • 備考:
    Species: Human, Applications: WB, IP
  • 参照:
    PubMed
  • No.: 28
  • 文献情報:
    Bilardi RA et al. Processing of anthracycline-DNA adducts via DNA replication and interstrand crosslink repair pathways. Biochem. Pharmacol. 2012 May;83(9):1241-50
    Bilardi RA et al
    2012/01/01
  • 備考:
    Species: Mouse, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 29
  • 文献情報:
    Jacquemont C et al. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Mol. Cancer 2012;11:26
    Jacquemont C et al
    2012/01/01
  • 備考:
    Species: Human, Applications: ICC/IF, WB
  • 参照:
    PubMed
  • No.: 30
  • 文献情報:
    Yang Y et al. Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9. Blood 2001 Dec;98(12):3435-40
    Yang Y et al
    2001/01/01
  • 備考:
    Species: Mouse, Applications: WB
  • 参照:
    PubMed
  • No.: 31
  • 文献情報:
    Stoepker C et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat. Genet. 2011 Feb;43(2):138-41
    Stoepker C et al
    2011/01/01
  • 備考:
    Species: Human, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 32
  • 文献情報:
    Jun DW et al. Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agents. PLoS ONE 2013;8(10):e75905
    Jun DW et al
    2013/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 33
  • 文献情報:
    Tomida J et al. A novel interplay between the Fanconi anemia core complex and ATR-ATRIP kinase during DNA cross-link repair. Nucleic Acids Res. 2013 May;
    Tomida J et al
    2013/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 34
  • 文献情報:
    Boisvert RA et al. Coordinate nuclear targeting of the FANCD2 and FANCI proteins via a FANCD2 nuclear localization signal. PLoS ONE 2013;8(11):e81387
    Boisvert RA et al
    2013/01/01
  • 備考:
    Species: Human, Applications: WB, ICC/IF
  • 参照:
    PubMed
  • No.: 35
  • 文献情報:
    Huard CC et al. The Fanconi anemia pathway has a dual function in Dickkopf-1 transcriptional repression. Proc. Natl. Acad. Sci. U.S.A. 2014 Feb;111(6):2152-7
    Huard CC et al
    2014/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 36
  • 文献情報:
    Bhat A et al. Rev3, the catalytic subunit of Polζ, is required for maintaining fragile site stability in human cells. Nucleic Acids Res. 2013 Feb;41(4):2328-39
    Bhat A et al
    2013/01/01
  • 備考:
    Species: Human, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 37
  • 文献情報:
    Kavanaugh GM et al. The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res. 2011 Sep;39(17):7465-76
    Kavanaugh GM et al
    2011/01/01
  • 備考:
    Species: Human, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 38
  • 文献情報:
    Zhang P et al. Non-erythroid alpha spectrin prevents telomere dysfunction after DNA interstrand cross-link damage. Nucleic Acids Res. 2013 May;41(10):5321-40
    Zhang P et al
    2013/01/01
  • 備考:
    Species: Human, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 39
  • 文献情報:
    Jones MJ et al. Dysregulation of DNA polymerase κ recruitment to replication forks results in genomic instability. EMBO J. 2012 Feb;31(4):908-18
    Jones MJ et al
    2012/01/01
  • 備考:
    Species: Human, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 40
  • 文献情報:
    Bekker-Jensen S et al. Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J. Cell Biol. 2006 Apr;173(2):195-206
    Bekker-Jensen S et al
    2006/01/01
  • 備考:
    Species: Human, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 41
  • 文献情報:
    Rego MA et al. Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor. Oncogene 2012 Jan;31(3):366-75
    Rego MA et al
    2012/01/01
  • 備考:
    Species: Human, Applications: WB, ICC/IF
  • 参照:
    PubMed
  • No.: 42
  • 文献情報:
    Jacquemont C et al. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res. 2007 Aug;67(15):7395-405
    Jacquemont C et al
    2007/01/01
  • 備考:
    Species: Human, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 43
  • 文献情報:
    Panneerselvam J et al. FAVL impairment of the Fanconi anemia pathway promotes the development of human bladder cancer. Cell Cycle 2012 Aug;11(15):2947-55
    Panneerselvam J et al
    2012/01/01
  • 備考:
    Species: Human, Applications: WB, ICC/IF
  • 参照:
    PubMed
  • No.: 44
  • 文献情報:
    Lyakhovich A et al. Constitutive activation of caspase-3 and Poly ADP ribose polymerase cleavage in fanconi anemia cells. Mol. Cancer Res. 2010 Jan;8(1):46-56
    Lyakhovich A et al
    2010/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 45
  • 文献情報:
    Wang Y et al. Structure analysis of FAAP24 reveals single-stranded DNA-binding activity and domain functions in DNA damage response. Cell Res. 2013 Oct;23(10):1215-28
    Wang Y et al
    2013/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 46
  • 文献情報:
    Gravells P et al. Reduced FANCD2 influences spontaneous SCE and RAD51 foci formation in uveal melanoma and Fanconi anaemia. Oncogene 2013 Jan;
    Gravells P et al
    2013/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 47
  • 文献情報:
    Baldeyron C et al. HP1alpha recruitment to DNA damage by p150CAF-1 promotes homologous recombination repair. J. Cell Biol. 2011 Apr;193(1):81-95
    Baldeyron C et al
    2011/01/01
  • 備考:
    Species: Human, Mouse, Applications: WB, ICC/IF
  • 参照:
    PubMed
  • No.: 48
  • 文献情報:
    Stiff T et al. Nbs1 is required for ATR-dependent phosphorylation events. EMBO J. 2005 Jan;24(1):199-208
    Stiff T et al
    2005/01/01
  • 備考:
    Species: Human, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 49
  • 文献情報:
    Wang Y et al. MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res. 2012 Aug;72(16):4037-46
    Wang Y et al
    2012/01/01
  • 備考:
    Species: Human, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 50
  • 文献情報:
    Bhagwat N et al. XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair. Mol. Cell. Biol. 2009 Dec;29(24):6427-37
    Bhagwat N et al
    2009/01/01
  • 備考:
    Species: Human, Applications: WB, ICC/IF
  • 参照:
    PubMed
  • No.: 51
  • 文献情報:
    Mason JM et al. Snm1B/Apollo functions in the Fanconi anemia pathway in response to DNA interstrand crosslinks. Hum. Mol. Genet. 2011 Jul;20(13):2549-59
    Mason JM et al
    2011/01/01
  • 備考:
    Species: Human, Applications: WB, ICC/IF
  • 参照:
    PubMed
  • No.: 52
  • 文献情報:
    Oda T et al. Hsp90 regulates the Fanconi anemia DNA damage response pathway. Blood 2007 Jun;109(11):5016-26
    Oda T et al
    2007/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 53
  • 文献情報:
    Taniguchi T et al. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 2002 Oct;100(7):2414-20
    Taniguchi T et al
    2002/01/01
  • 備考:
    Species: Human, Applications: WB, ICC/IF
  • 参照:
    PubMed
  • No.: 54
  • 文献情報:
    Wang Y et al. FANCM and FAAP24 Maintain Genome Stability via Cooperative as Well as Unique Functions. Mol. Cell 2013 Mar;49(5):997-1009
    Wang Y et al
    2013/01/01
  • 備考:
    Species: Human, Applications: WB, ICC/IF
  • 参照:
    PubMed
  • No.: 55
  • 文献情報:
    Taniguchi T et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 2003 May;9(5):568-74
    Taniguchi T et al
    2003/01/01
  • 備考:
    Species: Human, Applications: WB, IP, ICC/IF
  • 参照:
    PubMed
  • No.: 56
  • 文献情報:
    Brem R et al. Efficient DNA interstrand crosslinking by 6-thioguanine and UVA radiation. DNA Repair (Amst.) 2011 Aug;10(8):869-76
    Brem R et al
    2011/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 57
  • 文献情報:
    Coulthard R et al. Architecture and DNA recognition elements of the Fanconi anemia FANCM-FAAP24 complex. Structure 2013 Sep;21(9):1648-58
    Coulthard R et al
    2013/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 58
  • 文献情報:
    Figueiredo N et al. Anthracyclines induce DNA damage response-mediated protection against severe sepsis. Immunity 2013 Nov;39(5):874-84
    Figueiredo N et al
    2013/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 59
  • 文献情報:
    Donahue SL et al. A Rad50-dependent pathway of DNA repair is deficient in Fanconi anemia fibroblasts. Nucleic Acids Res. 2004;32(10):3248-57
    Donahue SL et al
    2004/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 60
  • 文献情報:
    Rego MA et al. Regulation of the Fanconi anemia pathway by a CUE ubiquitin-binding domain in the FANCD2 protein. Blood 2012 Sep;120(10):2109-17
    Rego MA et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 61
  • 文献情報:
    Duquette ML et al. CtIP is required to initiate replication-dependent interstrand crosslink repair. PLoS Genet. 2012;8(11):e1003050
    Duquette ML et al
    2012/01/01
  • 備考:
    Species: Human, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 62
  • 文献情報:
    Lensch MW et al. Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia. Blood 2003 Jul;102(1):7-16
    Lensch MW et al
    2003/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 63
  • 文献情報:
    Garcia-Higuera I et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 2001 Feb;7(2):249-62
    Garcia-Higuera I et al
    2001/01/01
  • 備考:
    Species: Human, Applications: WB, ICC/IF
  • 参照:
    PubMed
  • No.: 64
  • 文献情報:
    . ;

  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 65
  • 文献情報:
    Tremblay CS et al. HES1 is a novel interactor of the Fanconi anemia core complex. Blood 2008 Sep;112(5):2062-70
    Tremblay CS et al
    2008/01/01
  • 備考:
    Species: Human, Applications: WB, ICC/IF
  • 参照:
    PubMed
  • No.: 66
  • 文献情報:
    Fu D et al. Recruitment of DNA polymerase eta by FANCD2 in the early response to DNA damage. Cell Cycle 2013 Mar;12(5):803-9
    Fu D et al
    2013/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 67
  • 文献情報:
    Kolas NK et al. Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science 2007 Dec;318(5856):1637-40
    Kolas NK et al
    2007/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 68
  • 文献情報:
    Jacome A et al. Lac operator repeats generate a traceable fragile site in mammalian cells. EMBO Rep. 2011 Oct;12(10):1032-8
    Jacome A et al
    2011/01/01
  • 備考:
    Species: Mouse, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 69
  • 文献情報:
    Hoskins EE et al. The fanconi anemia pathway limits human papillomavirus replication. J. Virol. 2012 Aug;86(15):8131-8
    Hoskins EE et al
    2012/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 70
  • 文献情報:
    Kim Y et al. Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4. Blood 2012 Oct;
    Kim Y et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 71
  • 文献情報:
    Ying S et al. MUS81 promotes common fragile site expression. Nat. Cell Biol. 2013 Aug;15(8):1001-7
    Ying S et al
    2013/01/01
  • 備考:
    Species: Human, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 72
  • 文献情報:
    Kim Y et al. Mutations of the SLX4 gene in Fanconi anemia. Nat. Genet. 2011 Feb;43(2):142-6
    Kim Y et al
    2011/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 73
  • 文献情報:
    Olopade OI et al. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 2003 May;3(5):417-20
    Olopade OI et al
    2003/01/01
  • 備考:
  • 参照:
    PubMed